UFC fighter Cynthia Calvillo has been notified of a potential drug testing violation by the United States Anti-Doping Agency (USADA). The potential failed drug test was an in competition sample that was collected on the day of UFC 219, where she suffered a decision loss to former UFC Women's Strawweight Champion Carla Esparza.
Calvillo tested positive for a marijuana metabolite known as Carboxy-Tetrahydrocannabinol and she was found to be over the 180 ng/mL limit.
The UFC issued the following statement:
The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Cynthia Calvillo of a potential Anti-Doping Policy violation involving Carboxy-Tetrahydrocannabinol (“Carboxy-THC”) which is a metabolite of marijuana and/or hashish, above the decision limit of 180 ng/mL, stemming from an in-competition sample collected in conjunction with her recent bout in Las Vegas, Nevada on December 30, 2017, UFC 219: Cyborg vs. Holm.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Calvillo, as it relates to the UFC Anti-Doping Policy and future UFC participation. Because the Nevada Athletic Commission was the regulatory body overseeing the fight in Las Vegas and has licensing jurisdiction over Calvillo, USADA will work to ensure that the Nevada Athletic Commission has the necessary information to determine its proper judgment of Calvillo’s potential anti-doping violation. Additional information will be provided at the appropriate time as the process moves forward.
There has been no punishment handed to the fighter at this time and Calvillo has yet to comment on the matter. Since Calvillo lost the UFC 219 bout to Esparza, any punishment handed down would no affect the result of that encounter.
